financetom
Business
financetom
/
Business
/
Evercore strategists back dour S&P 500 view, expect weaker earnings outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Evercore strategists back dour S&P 500 view, expect weaker earnings outlook
Apr 15, 2024 9:20 AM

NEW YORK (Reuters) - U.S. earnings estimates are likely to weaken as companies issue cautious outlooks, according to Evercore ISI strategists, who stood by their view the S&P 500 will end the year well lower than current levels.

As first-quarter reporting season gets underway, 30 S&P 500 companies have posted results so far with a 6% earnings beat, according to BofA Global Research. Stocks slumped on Friday following results from several major banks, the first big day of the quarterly reporting season.

The S&P 500 through Friday had advanced 7.4% this year, and the stability in 2024 earnings estimates has been a supportive factor for stocks, Evercore equity and derivatives strategists led by Julian Emanuel said in a note.

But that is "unlikely to persist," the strategists said.

"We believe the corporate outlooks will be more guarded, and EPS revised lower," Evercore said in a research note on Sunday.

The strategists reiterated their year-end target for the S&P 500 of 4,750, about 7% below Friday's close of 5,123.41 for the benchmark index.

Current consensus estimates for earnings are optimistic even for a "no landing" economic scenario, Evercore said.

The strategists said they were defensively positioned, including "outperform" ratings on the consumer staples, healthcare and communication services sectors, as they anticipate "intensifying volatility."

Evercore's dour outlook comes while other strategists have boosted their S&P 500 targets in recent weeks as stocks have gotten off to a strong start this year.

The Wells Fargo Investment Institute on Monday raised their year-end S&P 500 forecast to a range of 5,100-5,300, up from 4,800-5,000 previously. WFII's strategists also lifted their targets for S&P 500 earnings and U.S. economic growth in 2024.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Snowflake's Talks to Acquire Reka AI Collapse
Market Chatter: Snowflake's Talks to Acquire Reka AI Collapse
May 22, 2024
04:25 PM EDT, 05/22/2024 (MT Newswires) -- Snowflake's (SNOW) discussions to purchase startup Reka AI for over $1 billion have collapsed, Bloomberg reported Wednesday, citing people aware of the situation. Snowflake and Reka did not respond to Bloomberg's comment requests. Snowflake and Reka did not immediately respond to MT Newswires' request for comments. (Market Chatter news is derived from conversations...
Loews Insider Sold Shares Worth $690,495, According to a Recent SEC Filing
Loews Insider Sold Shares Worth $690,495, According to a Recent SEC Filing
May 22, 2024
04:24 PM EDT, 05/22/2024 (MT Newswires) -- Richard Waldo Scott, Senior Vice President & Chief Investment Officer, on May 21, 2024, sold 9,045 shares in Loews ( L ) for $690,495. Following the Form 4 filing with the SEC, Scott has control over a total of 42,920 shares of the company, with 42,920 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/60086/000006008624000129/xslF345X03/wk-form4_1716409044.xml ...
--NVIDIA Q1 Data Center Revenue at $22.6 Billion vs Visible Alpha Analyst Consensus of $21.3 Billion; Gaming Revenue at $2.6 Billion vs Consensus of $2.62 Billion
--NVIDIA Q1 Data Center Revenue at $22.6 Billion vs Visible Alpha Analyst Consensus of $21.3 Billion; Gaming Revenue at $2.6 Billion vs Consensus of $2.62 Billion
May 22, 2024
04:24 PM EDT, 05/22/2024 (MT Newswires) -- Price: 989.80, Change: +40.30, Percent Change: +4.24 ...
Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing
Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing
May 22, 2024
04:25 PM EDT, 05/22/2024 (MT Newswires) -- Edward M. Kaye, Director, CEO, on May 20, 2024, sold 42,350 shares in Stoke Therapeutics ( STOK ) for $653,529. Following the Form 4 filing with the SEC, Kaye has control over a total of 27,000 shares of the company, with 27,000 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1623526/000141588924014087/xslF345X03/form4-05222024_080510.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved